These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37317594)

  • 1. SIK2: A critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer.
    Hu D; Du J; Xing Y; Cheng Y; He R; Liang X; Li H; Yang Y
    J Obstet Gynaecol Res; 2023 Aug; 49(8):2000-2009. PubMed ID: 37317594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
    Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIK2 enhances synthesis of fatty acid and cholesterol in ovarian cancer cells and tumor growth through PI3K/Akt signaling pathway.
    Zhao J; Zhang X; Gao T; Wang S; Hou Y; Yuan P; Yang Y; Yang T; Xing J; Li J; Liu S
    Cell Death Dis; 2020 Jan; 11(1):25. PubMed ID: 31932581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
    Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
    Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer.
    Zhao S; Zhang X; Shi Y; Cheng L; Song T; Wu B; Li J; Yang H
    J Exp Clin Cancer Res; 2020 Dec; 39(1):286. PubMed ID: 33317572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    Lu Z; Mao W; Yang H; Santiago-O'Farrill JM; Rask PJ; Mondal J; Chen H; Ivan C; Liu X; Liu CG; Xi Y; Masuda K; Carrami EM; Chen M; Tang Y; Pang L; Lakomy DS; Calin GA; Liang H; Ahmed AA; Vankayalapati H; Bast RC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35642638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MS4A15 acts as an oncogene in ovarian cancer through reprogramming energy metabolism.
    Fang Y; Yu H; Zhou H
    Biochem Biophys Res Commun; 2022 Apr; 598():47-54. PubMed ID: 35151203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
    Miranda F; Mannion D; Liu S; Zheng Y; Mangala LS; Redondo C; Herrero-Gonzalez S; Xu R; Taylor C; Chedom DF; Carrami EM; Albukhari A; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Salah E; Abdul Azeez KR; Elkins JM; Campo L; Myers KA; Klotz D; Bivona S; Dhar S; Bast RC; Saya H; Choi HG; Gray NS; Fischer R; Kessler BM; Yau C; Sood AK; Motohara T; Knapp S; Ahmed AA
    Cancer Cell; 2016 Aug; 30(2):273-289. PubMed ID: 27478041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of salt‑inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells.
    Ni X; Feng Y; Fu X
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34558647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
    Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
    Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
    Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
    Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
    Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
    Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
    Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
    Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
    [No Abstract]   [Full Text] [Related]  

  • 15. Salt-inducible kinase 2 and -3 are downregulated in adipose tissue from obese or insulin-resistant individuals: implications for insulin signalling and glucose uptake in human adipocytes.
    Säll J; Pettersson AM; Björk C; Henriksson E; Wasserstrom S; Linder W; Zhou Y; Hansson O; Andersson DP; Ekelund M; Degerman E; Stenkula KG; Laurencikiene J; Göransson O
    Diabetologia; 2017 Feb; 60(2):314-323. PubMed ID: 27807598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo.
    Park J; Yoon YS; Han HS; Kim YH; Ogawa Y; Park KG; Lee CH; Kim ST; Koo SH
    Diabetes; 2014 Nov; 63(11):3659-73. PubMed ID: 24898145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation.
    Shi M; Zhao M; Wang L; Liu K; Li P; Liu J; Cai X; Chen L; Xu D
    Phys Chem Chem Phys; 2021 Jun; 23(23):13216-13227. PubMed ID: 34086021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
    Matassa DS; Amoroso MR; Lu H; Avolio R; Arzeni D; Procaccini C; Faicchia D; Maddalena F; Simeon V; Agliarulo I; Zanini E; Mazzoccoli C; Recchi C; Stronach E; Marone G; Gabra H; Matarese G; Landriscina M; Esposito F
    Cell Death Differ; 2016 Sep; 23(9):1542-54. PubMed ID: 27206315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes.
    Henriksson E; Jones HA; Patel K; Peggie M; Morrice N; Sakamoto K; Göransson O
    Biochem J; 2012 Jun; 444(3):503-14. PubMed ID: 22462548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIK2 Promotes Ovarian Cancer Spread.
    Cancer Discov; 2016 Oct; 6(10):OF1. PubMed ID: 27604487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.